Featured Stories
Two Men Found Dead of Carbon Monoxide Poisoning

Two Men Found Dead of Carbon Monoxide Poisoning at Long Island, New York Auto Shop

Two men were found dead of apparent carbon monoxide poisoning in a Holbrook, New York, auto-detailing shop Thursday night, Suffolk County police say.

Read More

Image Source: wisegeek.com

Trial over Ethicon Transvaginal Mesh Begins in California

Pelvic mesh devices have become the subject of safety concerns in recent years amidst reports that they can cause serious, sometimes permanent injuries.

Read More

Fracking Boom Changing Way of Life in Pennsylvania's Northern Tier

In just a few years, the impact of hydraulic fracturing (fracking) drilling on northeastern Pennsylvania is hard to miss. Thousands of natural gas wells have been opened in that area specifically in the last five years as companies look to exploit the vast Marcellus shale formation about two miles below the ...

Read More

Zadroga Act Cancer Decision Expected This Week

The federal official tasked with determining what ailments should be covered by the federal Zadroga Act is expected to decide by Saturday if certain cancers will be eligible for compensation. The decision is being eagerly awaited by thousands of first responders who believe they developed cancer due to exposure ...

Read More

Actos, Avandia May Up Risk for Diabetic Macular Edema

A newly published study is raising concerns that patients who take Actos or Avandia may face an increased risk of developing diabetic macular edema, an eye disorder that can result in vision loss. The study, published in the Archives of Internal Medicine, found that type 2 diabetics who use thiazolidinediones, ...

Read More

Johnson & Johnson Marketing of Gynecare Prolift Transvaginal Mesh Raises More Questions

Johnson & Johnson and its Ethicon unit are again coming under scrutiny for the way it marketed its Gynecare ProLift transvaginal mesh product. According to a new report from Bloomberg News, Johnson & Johnson continued marketing the Gynecare ProLift device for months after it received a warning from the ...

Read More

Bisphosphonate Study Confirms Atypical Thigh Fracture Risk

New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a ...

Read More

Older Patients Face Heart Attack Risk Following Surgery

Older Hip Implant, Knee Replacement Patients Face Heart Attack Risk Following Surgery

An emerging report reveals that older hip implant and knee replacement patients face increased heart attack risks following surgery. The risk for acute myocardial infarction (AMI) was seen in the first two weeks after these surgical procedures.

Read More

Johnson & Johnson’s Ethicon Division to End Sales of Gynecare Prolift, Three Other Transvaginal Mesh Devices

Johnson & Johnson’s Ethicon Inc. division revealed yesterday that it will end sales of its Gynecare Prolift device and three other transvaginal mesh products. The plan to stop selling the four products was set forth in a letter filed by the company in the Ethicon transvaginal mesh multidistrict litigation ...

Read More

Levaquin Complaint can be Amended to Include FDA Warning, Court Says

In May 2016, the U.S. Food and Drug Administration (FDA) warned about the risks of fluoroquinolone antibiotics, which include Levaquin, Avelox and Cipro. The agency said that, given the risk of potentially permanent side effects, these medications should only be used in situations where no other treatment options are available for patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections.

Fluoroquinolones are the subject of a multidistrict litigation (MDL) underway in Minnesota. A court recently ruled that plaintiffs can amend the Master Complaint to include this most recent FDA announcement. At least 484 lawsuits have been filed over Levaquin, Cipro and Avelox in the District of Minnesota. An additional 40 lawsuits have been filed in state courts. Continue reading

Posted in Legal News |

Zithromax Linked to Rare but Extremely Serious Skin Side Effect

Zithromax, a widely prescribed antibiotic, has been linked to a number of severe side effects, including the serious allergic skin reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Stevens-Johnson is “a rare, serious disorder” of the skin and mucous membranes. SJS is usually a reaction to a medication or an infection. SJS frequently begins with flu-like symptoms, followed by a painful red or purplish rash that spreads and blisters. Continue reading

Posted in Health Concerns, Pharmaceuticals, Zithromax |

FDA Updates Abilify Label to Include Compulsive Behaviors

The U.S. Food and Drug Administration (FDA) has updated the warning label on Abilify, Abilify Maintena, Aristada and generic aripiprazole to include information about compulsive behavior. According to the safety announcement, there have been reports of uncontrollable urges to gamble, binge eat, shop and have sex in patients taking these drugs. According to the FDA announcement, the compulsive behaviors generally stopped when the dosage was lowered or drug discontinued.

The current label included pathological gambling as a reported side effect, but the FDA stated that this was not an accurate description of impulse-control problems identified. Additionally, the label did not include information about compulsive behaviors other than gambling. As a result, the agency is updating the warning label. Continue reading

Posted in Legal News |

FDA Revises Warning Label on Fluoroquinolone Antibiotics

The U.S. Food and Drug Administration (FDA) has approved labeling changes on fluoroquinolone antibiotics, which include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin and gemifloxacin (Factive). In a news release issued Tuesday, the agency said the Boxed Warning and the Warning and Precautions section of the label would be revised to warn of “disabling and potentially permanent side effects” affecting tendons, muscles, joints, nerves and the central nervous system.

Fluoroquinolones fight bacterial infections by preventing growth or killing bacteria. In November 2015, an FDA Advisory Committee reviewed new safety information involving two or more side effects that occur simultaneously, and the potential to lead to permanent damage. The committee concluded that the risks of fluoroquinolones generally outweighed the benefits in patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis and uncomplicated urinary tract infections. In May, the FDA released a drug safety communication stating that use of fluoroquinolones should be limited to situations where no alternative treatments are available.
The new safety label will reflect current information showing that both oral and injectable fluoroquinolones were associated with “disabling side effects” that can affect the tendons, muscles, joints, nerves and the central nervous system, the FDA said. The agency’s news release stated that the side effects may be permanent, and occur anywhere from hours to weeks after treatment. Continue reading

Posted in Legal News |

Zofran Birth Defect Lawsuit Update: “Sequence Discovery” Issue

Plaintiffs in more than 200 birth defect lawsuits have raised concerns over the pharmaceutical company GlaxoSmithKline’s (GSK) new proposal for Sequenced Discovery. Parents say the company neglected to warn patients and health experts of its anti-nausea drug Zofran’s alleged potential to cause serious birth defects, according to The Legal Examiner.

On June 3, 2016, GSK suggests possible order, or “sequence” in the document’s language, for how discovery should proceed. In the discovery phase, both parties are allowed to demand evidence from one another. For its part, GSK wants this litigation to turn to two major questions: Continue reading

Posted in Birth Defects, Health Concerns, Pharmaceuticals |

Dilantin Linked to Stevens-Johnson Syndrome, a Dangerous Skin Condition

Dilantin, the anti-epileptic drug that has been in use for decades is one of many drugs associated with the related skin conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Though these conditions are rare, when they do occur they put the patient at risk for permanent skin and organ damage and blindness. SJS/TEN can be fatal, Top Class Actions reports. Continue reading

Posted in Dilantin, Health Concerns, Lamictal, Pharmaceuticals, Zithromax |

Levaquin Plaintiffs Allowed to Include Updated FDA Safety Warnings in Legal Complaints

Hundreds of product liability lawsuits involving the fluoroquinolone antibiotics Levaquin, Cipro and Avelox are moving toward trial in a multidistrict litigation (MDL) in the U.S. District Court, District of Minnesota.

In June 2016, the court granted a motion from the plaintiffs to amend the master complaint to include information about the U.S. Food & Drug Administration’s (FDA) May 2016 safety announcement for fluoroquinolone antibiotics. The court said that doing so would not greatly expand the scope of the proceedings. Continue reading

Posted in Cipro, Legal News, Levaquin, Pharmaceuticals |

Xarelto Lawsuits Have Added Credibility Based on Scholarly Studies

The makers of Xarelto, an anticoagulant that was credited as a breakthrough in blood clot prevention, is battling numerous lawsuits. An alleged connection between an elevated risk for serious hemorrhages and Xarelto are now being lent possible increased credibility through recent studies, reports the Digital Journal.

The U.S. Food and Drug Administration (FDA) approved Xarelto in 2011. It is manufactured by Bayer AG and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The initial purpose of the medication was to prevent blood clots in patients with pulmonary embolisms, deep vein thrombosis, and those recovering from knee and hip replacement surgeries. A short while after it was approved, Xarelto’s uses were expanded to treat atrial fibrillation, a heart condition that increases the risk of stroke. Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals |

DePuy Orthopaedics Denied a Delay for September Pinnacle Hip Implant Trial

Texas federal Judge Ed Kinkeade has refused to delay the scheduled September trial in the ongoing multidistrict litigation involving DePuy Orthopaedics Pinnacle metal-on-metal (MoM) hip implants.

DePuy Orthopaedics requested the delay after a March trial resulted in a $502 million award to five plaintiffs who alleged serious injuries from DePuy Pinnacle hip devices. DePuy wanted the September trial delayed until the appeal of the March verdict had been decided but Judge Kinkeade ruled that the September trial would go forward. Continue reading

Posted in Defective Medical Devices, Depuy, Metal Hip Implants |

October 2017 Trial Expected in British Metal-on-Metal Hip Litigation

In one of Britain’s largest product liability group actions in recent years, lawyers for more than 600 individuals injured by early failure of metal-on-metal hip implants were in court recently for a hearing.

The lawyers for the plaintiffs in a number of metal-on-metal group actions met with legal representatives for major hip manufacturers including Smith & Nephew, Zimmer, Corin Cormet and DePuy Synthes (a subsidiary of Johnson & Johnson). Continue reading

Posted in Defective Medical Devices, Health Concerns, Metal Hip Implants |

© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.